TUCSON: AstraZeneca is currently testing a potential Alzheimer’s disease treatment the company estimates could generate peak sales of $5 billion, if approved.
The demand for Alzheimer’s treatments creates blockbuster potential for the drug, but AstraZeneca has conceded the medicine has just a 9 percent chance of regulatory approval in the uncertain drug development arena. A 2014 study found that 99.6 percent of possible Alzheimer’s treatments failed to reach the market between 2002 and 2012…